Supernus Pharm (SUPN)

$SUPN: The last close at $44.44 indicates a position near the 60D Low of $42.67, suggesting potential support. The RSI at 30.42 indicates oversold conditions, which may lead to a bullish reversal. The MA30 at $50.09 and MA50 at $48.61 are significantly above the current price, indicating downward momentum but also potential resistance levels to watch. Directional bias is cautiously bullish due to the oversold RSI and proximity to the 60D Low. Suggested entry is at $44.50, slightly above the last close to confirm buying interest. Set a stop loss at $42.50, just below the 60D Low to manage risk. Targets are $48.50 (near the MA50) and $50.00 (near the MA30), which align with potential resistance levels and provide a favorable risk-reward ratio. Monitor market conditions closely as price approaches these targets. https://privateprofiteers.com

$SUPN: The last close at $44.44 indicates a position near the 60D Low of $42.67, suggesting potential support. The RSI at 30.42 indicates oversold conditions, which may lead to a bullish reversal. The MA30 at $50.09 and MA50 at $48.61 are significantly above the current price, indicating downward momentum but also potential resistance levels to watch. Directional bias is cautiously bullish due to the oversold RSI and proximity to the 60D Low. Suggested entry is at $44.50, slightly above the last close to confirm buying interest. Set a stop loss at $42.50, just below the 60D Low to manage risk. Targets are $48.50 (near the MA50) and $50.00 (near the MA30), which align with potential resistance levels and provide a favorable risk-reward ratio. Monitor market conditions closely as price approaches these targets. https://privateprofiteers.com

$SUPN: The current market context shows a last close of $46.11, indicating a position below both the 30-day moving average (MA30) of $50.32 and the 50-day moving average (MA50) of $48.63. The RSI at 39.6 suggests that the stock is nearing oversold territory, which could indicate a potential reversal. The 60-day high of $57.65 and low of $41.78 provides a range that highlights significant resistance above the current price and support below. Directional bias leans bearish due to the price being below key moving averages, but the low RSI indicates a possible bounce. Suggested entry: $45.50 (slightly below the last close to confirm support). Stop: $41.50 (below the recent low). Targets: $48.00 (first target near MA50) and $50.00 (second target near MA30). Monitor for potential reversal signals given the oversold RSI. https://privateprofiteers.com

$SUPN: The current market context shows a last close of $46.11, indicating a position below both the 30-day moving average (MA30) of $50.32 and the 50-day moving average (MA50) of $48.63. The RSI at 39.6 suggests that the stock is nearing oversold territory, which could indicate a potential reversal. The 60-day high of $57.65 and low of $41.78 provides a range that highlights significant resistance above the current price and support below. Directional bias leans bearish due to the price being below key moving averages, but the low RSI indicates a possible bounce. Suggested entry: $45.50 (slightly below the last close to confirm support). Stop: $41.50 (below the recent low). Targets: $48.00 (first target near MA50) and $50.00 (second target near MA30). Monitor for potential reversal signals given the oversold RSI. https://privateprofiteers.com

$SUPN Share Price: $46.14 Contract Selected: Jun 18, 2026 $50 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.39 – $4.14 Potential Upside: 51% ROI Time to Expiration: 218 Days | Updates via https://fxcapta.com/stockinfo/

$CING Anyone else think $80 may actually be in line if they get PUFDA or im I just an idiot? $CING already has patents in these countries: Australia, Canada, Israel, and Europe. Add pending US, Korea and Hong Kong and your looking at a nice market share lock. $SUPN $AXSM have mc over $1B and I think $CING could hit that as well once given pufda. Interested to hear everyone's thoughts for long term

$SUPN - Supernus Pharmaceuticals Inc. Common Stock - 10Q - Updated Risk Factors SUPN updates tariff risk to focus on newly announced tariffs for pharmaceuticals, drops risks tied to 2025 drug pricing Executive Orders, and adds new warnings about costly, distracting legal actions. #Pharmaceuticals #RegulatoryChanges #LegalRisk #DrugPricing #TariffRisk 🟢 Added 🟠 Removed https://d-risk.ai/SUPN/10-Q/2025-11-06

$SUPN Lots of profit taking going on here on a quarter where they took some one-time charges that impacted bottom line, but actually improved guidance for the year. Big yellow flag was actually that they are having supply issues due to the success of one of their newer products. They need to get that resolved quickly so that revenue growth can continue.

$SUPN Supernus reports Q3 EPS (80c) vs. 69c last year -- Q3 revenue $192.1M, consensus $180.22M. -- Raises FY25 revenue view to $685M-$705M from $670M-$700M, consensus $702.59M. -- Raises FY25 adjusted operating earnings view to $125M-$145M from $105M-$135M.

$SUPN https://ir.supernus.com/news-releases/news-release-details/supernus-announces-third-quarter-2025-financial-results

$SUPN thing about it getting $LGND ary wen $XBI is in $RYTM 🐒🍌🧠⏰♾️

$SUPN "Heads up alert! Only three days until Upcoming earnings on Tuesday, 11/4/2025 for $SUPN Bullish (7.5) Supernus Pharmaceuticals (SUPN) is currently positioned as a strong contender in the specialty pharmaceuticals sector, particularly within the central nervous system (CNS) treatment space. The company has exhibited remarkable stock performance, with a one-year total shareholder return of approximately 54%, and a notable 55% increase over the past three months alone. This momentum is largely attributed to robust sales growth from its key products, Qelbree and GOCOVRI, which have been instrumental in exceeding revenue expectations. The company’s P/E ratio stands at a competitive level compared to its peers, reflecting its growth potential and operational efficiency. Moreover, analysts have noted a positive earnings surprise history for SUPN, which bodes well for future performance. The latest earnings forecast suggests a slight decline in earnings, yet this has not dampened investor sentiment, as evidenced by recent upgrades from financial analysts, including a shift from ""Neutral"" to ""Overweight"" by Piper Sandler. In terms of upcoming earnings reports, Supernus Pharmaceuticals is set to announce its third-quarter financial results on November 4, 2025. Analysts are cautiously optimistic, anticipating a decline in earnings but maintaining a focus on the company’s ability to leverage its CNS drug pipeline effectively. Historical performance indicates that SUPN has often surpassed earnings estimates, which could play a significant role in shaping market expectations. Consensus estimates suggest a slight contraction in earnings, yet the strong sales trajectory of its flagship products may mitigate the impact of this anticipated decline. Investors are particularly keen on how management addresses growth strategies and responds to market dynamics during the earnings call. Overall, the specialty pharmaceuticals sector has shown resilience and growth potential, bolstered by innovative product pipelines and increasing demand for CNS-related treatments. This sector's performance has been strong, with many companies, including Supernus, capitalizing on emerging trends and shifting consumer needs. As such, SUPN's positioning within this landscape, coupled with its operational strengths, suggests a favorable outlook for investors. - Funds were net buyers of $SUPN during the previous reporting quarter. - Funds with large holdings in $SUPN include: - Armistice Capital LLC, MV: $152MM. Fund Rank: 72% www.armisticecapital.com - GW&K Investment Management LLC, MV: $40MM. Fund Rank: 76% - Rubric Capital Management LP, MV: $22MM. New position. Fund Rank: 92% www.rubriccapital.com - Point72 Asset Management LP, MV: $16MM. Fund Rank: 91% www.point72.com - Krensavage Asset Management LLC, MV: $15MM. Fund Rank: 65% www.krensavage.com - Last 10 days performance: 9% - Last 30 days performance: 15% - Last 90 days performance: 55% Some of the latest news articles: - Title: Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for Publication Date: 10/30/2025 2:00:28 PM, Source: yahoo URL: https://finance.yahoo.com/news/analysts-estimate-amphastar-pharmaceuticals-amph-140028727.html?.tsrc=rss - Title: 3 Cash-Producing Stocks That Fall Short Publication Date: 10/30/2025 4:32:31 AM, Source: yahoo URL: https://finance.yahoo.com/news/3-cash-producing-stocks-fall-043231382.html?.tsrc=rss - Title: BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates Publication Date: 10/29/2025 9:15:01 PM, Source: yahoo URL: https://finance.yahoo.com/news/bridgebio-pharma-bbio-reports-q3-211501816.html?.tsrc=rss - Title: Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News? Publication Date: 10/29/2025 5:54:40 PM, Source: yahoo URL: https://finance.yahoo.com/news/supernus-pharmaceuticals-sustain-momentum-13-175440241.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."

$SUPN Opportunity TD Cowen raises target price to $60 from $45

TD Cowen has adjusted their stance on Supernus Pharmaceuticals ( $SUPN ), setting the rating to Buy with a target price of 45 → 60.

Piper Sandler upgrades $SUPN to Overweight and raises its price target to $65 from $40. The boost is driven by excitement over its new Onapgo pump for Parkinson's disease, seen as a major profit driver. 💊

Piper Sandler has updated their rating for Supernus Pharmaceuticals ( $SUPN ) to Overweight with a price target of 65.

$CING I have to add $COLL as a potential buyer/partner. The new Chief Legal Officer, Nilay Patel, comes from Ironshore Pharm, which Collegium acquired to expand its presence in the ADHD/CNS space. This is getting very interesting… my Money is with COLL or $SUPN. I'm done with my DD. Happy trading, nothing else to add.

$CING IMO, Cingulate is for sale. The latest moves by Bod/executives are telling the story. COO out, Expert in deals hired-CLO( check Ironshore Pharm-Buyout), problematic CEO out, Interim CFO-CEO. The ADHD market is too lucrative for current players in the CNS space to let a new player capture a significant portion of their market share. Who in the CNS space could be the buyer? I will go with $SUPN, Otsuka, or maybe a division of JNJ. Anyone with other potential players?

$SUPN: Unusual Options Activity Alerted CALL flow observed 203x contracts at Strike price of $48 Exp on 11/21/2025 with Premium of $81K and showing BEARISH Sentiment

$SUPN Jefferies raises target price to $55 from $45

sld some stocks (partial) to raise cash. sld $BABA for a 115% gain; sld $CIEN for a 200% gain; sld $MPWR for a 130% gain; sld $ROKU for a 45% loss; sld $SUPN for a 105% gain;